Cancer Informatics

期刊全称Cancer Informatics
涉及主题生物遗传学计算机科学医学化学生物化学基因内科学数学计算生物学生物信息学癌症统计人工智能数据挖掘病理机器学习基因表达工程类程序设计语言
期刊介绍

The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.

期刊ISSNprint: 1176-9351
历年影响因子
2024年 2023年 2022年 2021年 2020年 2019年 2018年 2017年
2.42000000
历年发表/被引量
年份20252024202320222021202020192018201720162015201420132012
发表量9243640191834223534751101513
被引量291974107810411111948994865799701606447411322
h-Index0
自引率4.20%
涉及的研究领域Medicine-Oncology
中科院2025年分区 ?
大类小类TOP期刊综述期刊
4区4区 数学与计算生物学
4区肿瘤学
WOS期刊分区

JCR学科分类

JCR分区学科名称收录数据库JCR分区分区排名
MATHEMATICAL & COMPUTATIONAL BIOLOGYESCIQ223/67
ONCOLOGYESCIQ3188/326

JCI学科分类

JCI分区学科名称收录数据库JCI分区分区排名
MATHEMATICAL & COMPUTATIONAL BIOLOGYESCIQ338/67
ONCOLOGYESCIQ3180/326
期刊主页https://journals.sagepub.com/home/cixhttp://insights.sagepub.com/journal-cancer-informatics-j10
出版商Libertas Academica
出版国家(地区)United Kingdom
出版语言English
每年出版文章数18
Gold OA文章占比91.11%
原创研究文献占比
(排除综述)
94.34%
SCI收录类型

Emerging Sources Citation Index (ESCI)

Scopus (CiteScore)

Directory of Open Access Journals (DOAJ)

PubMed链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1176-9351%5BISSN%5D
平均审稿周期8 Weeks
相关链接

您可以在上述网站查看该期刊的网友互动,及期刊影响力的其它指标。

注:上述信息均来源于网络,仅供查考,如有遗漏或信息错误,欢迎 向我反馈